H istone deacetylases (HDACs) are a class of enzymes modulating gene expression via deacetylation of both histone and nonhistone proteins, and thereby, these enzymes are involved in a wide range of biological processes.
1−3 Many HDAC inhibitors have shown excellent properties for tumor therapy in clinical trials. To date, 18 mammalian HDAC subtypes have been discovered and accordingly classified into four classes based upon their phylogeny. 4, 5 Class I (HDACs 1− 3 and 8), class IIa HDACs (4, 5, 7, and 9), class IIb HDACs (6 and 10), and the class IV (11) are Zn-dependent hydrolases, whereas class III (sirtuins 1−7) enzymes are NAD + -dependent Sir2-like deacetylases. 5 Class I HDACs are mostly localized within the nucleus, whereas class II HDACs shuttle between nucleus and cytoplasm. HDAC isoforms are highly expressed in various cancers, including breast cancer, pancreatic cancer, colorectal cancer, prostate cancer, and hepatocellular carcinoma.
6−8 Treatment of tumor cells with HDAC inhibitors results in growth arrest, differentiation, and apoptosis, promoting these enzymes as potential cancer drug targets. 9, 10 HDAC inhibitors (HDACi) are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids, and benzamides. 11 So far, more than 11 new HDACi are in various stages of clinical development for therapy of multiple cancer types. 12 Among them, suberoylanilide hydroxamic acid (SAHA, Vorinostat, Merck Research Laboratories) and FK228 (Romidepsin, Celgene) 2 have been approved by US FDA for the treatment of cutaneous T-cell lymphoma. To evaluate the efficiency of existing and novel HDACi and acquire important basic scientific insight of biological and molecular events of HDACs, there is an increasing need for HDAC targeting imaging probes. To date, limited noninvasive HDAC imaging probes were reported for cancer diagnosis and therapy evaluation of HDACi in vivo. 13 For example, in Figure 1 14,15 18 F-suberoylanilide hydroxamic acid ( 18 F-SAHA) was reported to be able to evaluate the target efficacy of HDAC inhibitor SAHA within 24 h of drug administration in a murine ovarian cancer model. 16 Breast cancer is one of the leading causes of cancer death in women. Recent studies found that HDACs were correlated with estrogen receptor (ER) and progesterone receptor (PR) expression, and its expression enabled a more precise assessment of the prognosis of breast cancer patients. 17, 18 Introducing HDACi in breast cancer treatment could overcome resistance to hormonal therapy. 19 HDACi was also reported to selectively target triple-negative breast cancer cell proliferation and survival in vitro and tumorigenesis in vivo. 20 HDACs as a promising biomarker play an increasingly important role in breast cancer treatment. For breast cancer imaging, targeted ER and human epidermal growth factor receptor 2 (HER2) imaging probe is currently under intense preclinical and clinical investigation; however, these agents only apply to ER or HER2-positive subtypes. 21 64 Cu]7 developed from a HDACi, 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101, Selleckchem, TX), which is currently in phase I clinical trials with multiple tumor types including advanced breast cancer. 22, 23 As a member of hydroxamates HDACi, CUDC-101 has the distinguishing characteristics including a hydroxamic acid group interacting with zinc at the active site of HDACs to interfere with enzyme activity, carbon linker, and capping group. 24 The capping group is solvent-exposed and interacts with amino acids near the entrance of the active site. 25, 26 In this study, chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA, Macrocyclics, TX) was conjugated to CUDC-101 with a hydrophobic carbon chain linker by click reaction. Our synthesis started from commercially available CUDC-101, which was then reacted with a carbon chain linker bearing an azide group at one end as well as a primary amine group at the other end. After the introduction of the linker, compound 9 was conjugated to DOTA-NHS in the presence of NEt 3 to give compound 7 (Scheme 1) (Supporting Information).
We subsequently determined HDAC binding activity of compound 7 using the Fluor-de-Lys HDAC Fluorimetric Assay/Drug Discovery Kit (Enzo Life Sciences, NY). The IC 50 value of 7 was measured as 94.47 ± 19.24 nM (Supporting Information Figure S1 ). This finding thus identified 7 as a promising candidate for the development of 64 Cu HDAC targeting PET imaging probe. Compound 7 was radiolabeled by incubating with 64 CuCl 2 (Washington University, MO) in 0.1 N NaOAc buffer (pH 5.5) at 60°C for 1 h (Scheme 1). 64 Cu]7 with increasing concentration of HDAC inhibitor CUDC-101 using MDA-MB-231, a triple-negative human breast cancer cell line with high HDACs expression. 27 The cellular retention and internalization of radioactivity was determined using a γ counter (Perkin-Elmer Packard, CT). The results showed that the cell uptake of [ 64 Cu]7 decreased along with the increasing of the CUDC-101 concentration, which provided evidence for target-mediated binding to HDAC-expressing cells (Figure 2 ). This competitive cell binding assay that established the cell uptake of [ 64 Cu]7 was realized by its specific binding to HDAC in vitro.
The in vivo imaging of mice bearing human triple-negative breast cancer MDA-MB-231 xenograft tumors was carried out 64 Cu]7 had the high uptake in the liver, kidney, and tumor, with relatively low distribution in other tissues at 24 h p.i. Region-of-interest (ROI) analysis on microPET images showed that the tumor uptake values were 1.20 ± 0.21, 2.16 ± 0.08, and 2.36 ± 0.31% ID/g at 2, 6, and 24 h p.i., respectively (Figure 3b) The MDA-MB-231 tumor uptake values for blocking experiments were 0.48 ± 0.24, 0.94 ± 0.37, and 1.22 ± 0.31% ID/g at 2, 6, and 24 h p.i., respectively, which showed significant decreasing compared with that of the imaging group at all time points (Figure 3b ). In the blood clearance study shown in Figure S2 (Supporting Information), [
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64 Cu]7 was rapidly cleared from the blood. The rapid clearance continued until 30 min postinjection when only 6% ID/g was left in the blood. We subsequently determined the tissue distribution of [ 64 Cu]7 by sacrificing the mice at 24 h p.i. immediately after microPET/CT scans. Tumor, organs, and tissues of interest were excised and weighed; the radioactivity of harvested tissues was measured using γ-counter (Perkin-Elmer Packard, CT). The decay-corrected %ID/g of organs and tumors are shown in Table 1 .
The biodistribution result demonstrated that the tumor uptake of [ 64 Cu]7 reached 2.21 ± 0.19%ID/g at 24 h p.i. in the imaging group, whereas the presence of nonradioactive CUDC-101 significantly reduced the tumor uptake to 1.36 ± 0.23% ID/g (P < 0.01) in the blocking group with a 38% decrease. For the imaging group (nonblocking), 3.23 ± 1.25% ID/g and 1.90 ± 0.06% ID/g remained in the liver and kidneys, respectively. The overall uptake of [
64 Cu]7 in other tissues and organs of blocking group was similar to that of the nonblocking group. On the basis of the biodistribution results, the contrast ratio of tumor to muscle for the imaging groups was calculated as 9.61 ± 1.53, which made tumors clearly visible at 24 hs p.i. as shown in Figure 3a . Meanwhile, the corresponding value for the blocking group was 5.70 ± 0.48 with a 38% decrease. These data proved the HDAC specific binding of [ 64 Cu]7 in vivo. The biodistribution results were consistent with the quantitative analysis of microPET imaging.
In conclusion, we reported, to our knowledge, the first 64 Cu labeled probe [
64 Cu]7 for PET imaging of HDACs in vivo using a triple-negative breast cancer xenograph model. From the enzymatic assay, the IC 50 of this compound to HDACs was shown to be in the nanomolar range, which indicated the remaining HDAC activity during structure modification from HDAC inhibitor CUDC-101. The specific binding of radiolabeled probe [
64 Cu]7 to HDACs was proven by the competition of [
64 Cu]7 with increasing concentration of CUDC-101 using MDA-MB-231 breast cancer cells. Micro-PET/CT imaging revealed rapid and high [
64 Cu]7 uptake in MDA-MB-231 breast tumors, and HDAC specificity in vivo was also confirmed by blocking experiments. This proof-of-concept research demonstrated the feasibility of using small molecule HDAC inhibitor for HDAC imaging probe development. Further optimization of [ 64 Cu]7 by using different Cu chelators to achieve better distribution and tumor uptake will be performed in a following study. The success of HDAC specific imaging in breast cancer using [
64 Cu]7 has potential to be translated in clinical applications to noninvasively document 
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